Related Experiment Video

Updated: Jun 22, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Targeted therapies in the treatment of advanced renal cell carcinoma

Emmanuel Seront1, Jean-Pascal Machiels

  • 1Centre du Cancer, Department of Medical Oncology, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium.

Recent Patents on Anti-Cancer Drug Discovery
|June 13, 2009
PubMed

Insights

Targeted therapies like bevacizumab, sorafenib, sunitinib, everolimus, and temsirolimus improve progression-free survival for metastatic clear cell renal cell carcinoma (RCC). These agents offer effective treatment options for patients with advanced kidney cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Renal cell carcinoma (RCC) is a significant cause of cancer mortality.
  • Clear cell RCC is the predominant histological subtype.
  • Advances in understanding RCC molecular pathways have enabled targeted therapy development.

Purpose of the Study:

  • To provide a comprehensive review of novel targeted therapies for metastatic unresectable renal cell carcinoma.
  • To discuss the efficacy and application of new medications in clinical practice.
  • To examine relevant patents associated with these targeted therapies.

Main Methods:

  • Literature review of clinical trials and studies on targeted therapies for RCC.
  • Analysis of progression-free survival (PFS) data for key medications.
  • Discussion of treatment guidelines and patent landscape.

Main Results:

  • Five targeted therapies (bevacizumab, sorafenib, sunitinib, everolimus, temsirolimus) demonstrate improved PFS in metastatic clear cell RCC.
  • Bevacizumab, sunitinib, and temsirolimus are effective first-line treatments.
  • Sorafenib and everolimus show efficacy in patients with prior treatment failure.

Conclusions:

  • New targeted therapies represent a significant advancement in treating metastatic renal cell carcinoma.
  • These medications offer improved outcomes for patients with advanced disease.
  • Understanding the molecular basis of RCC is crucial for developing effective treatments.

More Related Videos

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...